Back to Search

TAYLOR MOODY, PHARM.D

PHARM.D

Pharmacist

NPI: 1396359303Individual

Specialties, Licenses & Credentials

PharmacistPrimary

Pharmacist

Code: 183500000X

21186(AL)

Research & Publications (20)

Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
PMID 19628293·Lung Cancer·2010
7-preclinical
Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.
PMID 18336841·Life Sci·2008
7-preclinical
Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
PMID 17580098·Peptides·2007
7-preclinical
Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.
PMID 17567944·Ann N Y Acad Sci·2007
7-preclinical
Breast cancer VPAC1 receptors.
PMID 16888206·Ann N Y Acad Sci·2006
8-other
In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.
PMID 16766720·J Pharmacol Exp Ther·2006
7-preclinical
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
PMID 16691010·J Mol Neurosci·2006
7-preclinical
Peptide hormones and lung cancer.
PMID 16633328·Panminerva Med·2006
6-review
Valence and anion binding of bovine ribonuclease A between pH 6 and 8.
PMID 15620889·Anal Biochem·2005
7-preclinical
The development of VIP-ellipticine conjugates.
PMID 15518911·Regul Pept·2004
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
1537 S US HIGHWAY 231
OZARK, AL 36360

Quick Facts

NPI
1396359303
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile